TCF20

Across TCGA pan-cancer cohorts, TCF20 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated TCF20 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher TCF20 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated TCF20 expression acts as an unfavorable survival marker, although some lineages such as UCEC and CESC show a favorable association.

UCEC, LIHC, and PRAD are the cancer types where TCF20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.843	0.617	.003	16	view →
LIHC	DFS	Median	All	0.089	0.535	<.001	9	view →
PRAD	DFS	Median	All	0.648	0.936	.001	6	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	6	view →
ESCA	DFS	Median	III,IV	0.080	0.442	<.001	6	view →
SKCM	OS	Median	III,IV	0.138	0.841	<.001	6	view →
CESC	DFS	Median	All	1.000	0.810	.030	2	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

TCF20–UCEC (DFS)

Open the UCEC breakdown →